VCM
RXRX icon

Voleon Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Voleon Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.4K Sell
21,894
-65,954
-75% -$220K ﹤0.01% 752
2026
Q1 		$270K Buy
87,848
+60,255
+218% +$233K 0.01% 684
2025
Q4 		$113K Buy
+27,593
New +$137K ﹤0.01% 749

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Voleon Capital Management's RXRX Position: Q2 2026 in Review

Voleon Capital Management reduced its Recursion Pharmaceuticals (RXRX) stake by 75% in Q2 2026, selling an estimated $220K and leaving 21,894 shares worth $80.4K. The position accounts for ﹤0.01% of the portfolio, ranked #752.

Voleon Capital Management first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $270K in Q1 2026. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Voleon Capital Management held 21,894 shares of Recursion Pharmaceuticals worth $80.4K as of Q2 2026.
  • Voleon Capital Management sold 65,954 Recursion Pharmaceuticals shares in Q2 2026, an estimated $220K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Voleon Capital Management's portfolio in Q2 2026, its #752 holding.
  • Voleon Capital Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Voleon Capital Management's Recursion Pharmaceuticals position peaked at $270K in Q1 2026.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.